Coherus BioSciences agrees to retract restraining order against AbbVie

Coherus BioSciences said on June 22 it had agreed to retract a restraining order against AbbVie regarding the launching of a lower-priced version of rheumatoid arthritis drug Humira, according to a Yahoo report.

The report noted that in early June Coherus said that it would release a biosimilar version of AbbVie's Humira, at an 85% discount to the list price of about $6,922, and partnered with Mark Cuban Cost Plus Drug Company to sell it at $569.27.

[Read more: Mark Cuban Cost Plus Drug Company partners with Coherus to offer Humira biosimilar]

AbbVie had alleged a breach of an older agreement that granted Coherus a non-exclusive license to commercialize a biosimilar version of Humira in the United States from July 1. In response, Coherus filed a restraining order against AbbVie to keep it from terminating the licensing deal, per the report.

[Read more: Celltrion USA obtains FDA nod for Humira biosimilar]

This was followed by a preliminary injunction against Coherus, which still remains in place, though the companies have agreed that AbbVie would not terminate its licensing deal based on the notice. The companies also agreed that AbbVie would have to serve another notice and give Coherus time to resolve the breach if it chooses to terminate the licensing agreement, the report said.